

GP1646/8

Docket No.: PF-0339-1 DIV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 5/10/00

By: Crystal Susa Printed: CRYSTAL SUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bandman et al.

Title: NEW HUMAN INTEGRAL MEMBRANE PROTEIN

Serial No.: 09/265,710

Filing Date: March 9, 1999

Examiner: Ulm, J.

Group Art Unit: 1646

RECEIVED

MAY 09 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Amendment Transmittal Fee Sheet (1pg., in duplicate);
3. Response to Restriction Requirement (5pp., in duplicate).

The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate Fee	Additional Fee(s)
Total Claims	29	-	20	=	9	\$18	\$162
Indep. Claims	4	-	3	=	1	\$78	\$78
___ First Presentation of Multiple Dependent Claim						+\$260	\$

TOTAL \$ 240.00

X Please charge Deposit Account No. 09-0108 the amount of \$ 240.00

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. **09-0108**. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.


Date: 1 Mar 2000

Adam Warwick Bell, D.Phil.

Reg. No. 43,490

Direct Dial Telephone: (650) 621-7542

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886



Docket No.: PF-0339-1 DIV

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 5/10/00.

By: Crystal Luna
Printed: CRYSTAL LUNA

C/6
TDP
5-10-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bandman et al.

Title: NEW HUMAN INTEGRAL MEMBRANE PROTEIN

Serial No.: 09/265,710

Filing Date: March 9, 1999

Examiner: Ulm, J.

Group Art Unit: 1646

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

Sir:

This is in response to the Restriction Requirement and Request for Election mailed 4/30/00, setting a 1 month term for response, making a response due on or before Monday, 5/1/00.

Applicants hereby elect, with traverse, to prosecute Group I, which includes and is drawn to Claims 1, 2, and 12, directed to polypeptides. Applicants reserve the right to prosecute the subject matter of non-elected claims in subsequent divisional applications. Applicants traverse on the ground that it would not produce a serious burden on the Examiner to examine the claims of Group I together with the claims Groups II and V (encompassing an antibody that binds specifically with the polypeptide of claim 1, and method of treatment using the protein of claim 12, respectfully), rather it would produce a more efficient prosecution of closely related subject matter.

IN THE CLAIMS

Please add the following new claims:

05/08/2000 SLUANG1 00000079 090108 09265710

01 FC:103 57778 162.00 CH
02 FC:102 78.00 CH